Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1896 1
1935 1
1947 1
1949 1
1950 1
1951 2
1954 1
1965 1
1966 1
1969 1
1970 3
1971 2
1972 1
1973 1
1974 2
1975 6
1976 5
1977 4
1978 5
1979 1
1980 2
1981 2
1982 2
1983 2
1984 3
1985 7
1986 4
1987 1
1988 6
1989 2
1990 2
1991 1
1992 2
1993 8
1994 7
1995 3
1996 9
1997 3
1998 9
1999 5
2000 5
2001 5
2002 8
2003 2
2004 5
2005 8
2006 13
2007 19
2008 11
2009 16
2010 13
2011 11
2012 18
2013 29
2014 30
2015 26
2016 33
2017 27
2018 25
2019 33
2020 27
2021 25
2022 49
2023 37
2024 57
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean c c addition (353,329 results)?
Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.
Betterle C, Presotto F, Furmaniak J. Betterle C, et al. J Endocrinol Invest. 2019 Dec;42(12):1407-1433. doi: 10.1007/s40618-019-01079-6. Epub 2019 Jul 18. J Endocrinol Invest. 2019. PMID: 31321757 Review.
BACKGROUND: Addison's disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by autoimmunity. ...
BACKGROUND: Addison's disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by au …
Addison's Disease: Diagnosis and Management Strategies.
Carsote M, Nistor C. Carsote M, et al. Int J Gen Med. 2023 Jun 2;16:2187-2210. doi: 10.2147/IJGM.S390793. eCollection 2023. Int J Gen Med. 2023. PMID: 37287503 Free PMC article. Review.
We aim to overview Addison's disease (AD) with regard to current diagnosis and management. This is a narrative review of full-length articles published in English between January 2022 and December 2022 (including online ahead of print versions) in PubMed-indexed journals. …
We aim to overview Addison's disease (AD) with regard to current diagnosis and management. This is a narrative review of full-length …
Medical Device-Related Pressure Injuries.
Pittman J, Gillespie C. Pittman J, et al. Crit Care Nurs Clin North Am. 2020 Dec;32(4):533-542. doi: 10.1016/j.cnc.2020.08.004. Epub 2020 Oct 7. Crit Care Nurs Clin North Am. 2020. PMID: 33129412 Review.
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association.
Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspry KE, Bolick JP, Kris-Etherton PM, Maki KC. Kirkpatrick CF, et al. J Clin Lipidol. 2023 Jul-Aug;17(4):428-451. doi: 10.1016/j.jacl.2023.05.099. Epub 2023 Jun 2. J Clin Lipidol. 2023. PMID: 37271600 Free article. Review.
Lowering LDL-C and non-high-density lipoprotein cholesterol are the primary objectives for reducing ASCVD risk. ...Nutrition interventions for addressing concurrent elevations in LDL-C and TG include a combination of the strategies described for lowering LDL-C …
Lowering LDL-C and non-high-density lipoprotein cholesterol are the primary objectives for reducing ASCVD risk. ...Nutrition interven …
Saturated fats and cardiovascular health: Current evidence and controversies.
Maki KC, Dicklin MR, Kirkpatrick CF. Maki KC, et al. J Clin Lipidol. 2021 Nov-Dec;15(6):765-772. doi: 10.1016/j.jacl.2021.09.049. Epub 2021 Oct 1. J Clin Lipidol. 2021. PMID: 34649831
A diet high in saturated fatty acids (SFA) is a suspected contributor to atherosclerotic cardiovascular disease (ASCVD) risk, in large part because of an effect to raise the low-density lipoprotein cholesterol (LDL-C) concentration. Most dietary guidance from health author …
A diet high in saturated fatty acids (SFA) is a suspected contributor to atherosclerotic cardiovascular disease (ASCVD) risk, in large part …
New Approach to Addison Disease: Oral Manifestations Due to Endocrine Dysfunction and Comorbidity Burden.
Bugălă NM, Carsote M, Stoica LE, Albulescu DM, Ţuculină MJ, Preda SA, Boicea AR, Alexandru DO. Bugălă NM, et al. Diagnostics (Basel). 2022 Aug 28;12(9):2080. doi: 10.3390/diagnostics12092080. Diagnostics (Basel). 2022. PMID: 36140482 Free PMC article. Review.
This review highlights oral anomalies with major clinical impact in Addison disease (AD), including dental health and dermatologic features, through a dual perspective: pigmentation issues and AD comorbidities with oral manifestations. ...
This review highlights oral anomalies with major clinical impact in Addison disease (AD), including dental health and dermatologic fe …
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Kastelein JJP, et al. Curr Atheroscler Rep. 2024 Feb;26(2):35-44. doi: 10.1007/s11883-023-01184-1. Epub 2023 Dec 22. Curr Atheroscler Rep. 2024. PMID: 38133847 Free PMC article. Review.
In ROSE2, 10 mg obicetrapib monotherapy and combined with 10 mg ezetimibe, each on top of HIS, significantly reduced low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, total LDL particles, small LDL p …
In ROSE2, 10 mg obicetrapib monotherapy and combined with 10 mg ezetimibe, each on top of HIS, significantly reduced low-density lipoprotein …
Primary adrenal insufficiency: New genetic causes and their long-term consequences.
Buonocore F, Achermann JC. Buonocore F, et al. Clin Endocrinol (Oxf). 2020 Jan;92(1):11-20. doi: 10.1111/cen.14109. Epub 2019 Oct 30. Clin Endocrinol (Oxf). 2020. PMID: 31610036 Free PMC article. Review.
We discuss (a) the role of the nuclear receptors DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human adrenal and reproductive dysfunction; (b) multisystem growth restriction syndromes due to gain-of-function in the growth repressors CDKN1C (IMAGE syndrome) and SAMD9 ( …
We discuss (a) the role of the nuclear receptors DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human adrenal and reproductive dy …
LDL-C Estimation: The Perils of Living With Imperfection.
Maki KC, Grant JK, Orringer CE. Maki KC, et al. J Am Coll Cardiol. 2022 Feb 15;79(6):542-544. doi: 10.1016/j.jacc.2021.12.005. J Am Coll Cardiol. 2022. PMID: 35144745 Free article. No abstract available.
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, Curcio DL, Maki KC, Davidson MH, Nicholls SJ. Ballantyne CM, et al. J Clin Lipidol. 2023 Jul-Aug;17(4):491-503. doi: 10.1016/j.jacl.2023.05.098. Epub 2023 Jun 3. J Clin Lipidol. 2023. PMID: 37277261 Free article. Clinical Trial.
BACKGROUND: Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein particles, and apolipoproteins, when added to high-intens …
BACKGROUND: Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL- …
594 results